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Highlights 
A classificatory literature review on medicines reverse flows is performed. 
Excessive production/demand uncertainty jeopardize medicines reverse flows. 
Cordination of the forward supply chain is pivotal for medicines reverse logistics. 
Green chemistry is a form of circular economy in pharmaceutical supply chain. 
Failures in monitoring of prescriptions hinder the circularity of medicines. 
Circular economy of medicines requires deeper investigation as business opportunity. 
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Abstract 
The Pharmaceutical Supply Chain (PSC) is responsible for considerable environmental 
and product-value impacts. However, studies on the reverse flows of PSC do not capture 
the diverse routes of end-of-use and end-of-life medicines (EOU/EOL-M) and how the 
constraints in the forward supply chain processes and operations impact such reverse 
flows. This research proposes a classificatory review in which three categories of reverse 
flows are identified: donations, Reverse Logistics (RL) and Circular Economy (CE). 
Donations are characterized by explicit philanthropic acts involving corporate reputation 
or by emergency humanitarian action. RL is boosted by regulatory issues and restricted 
by business imperatives of the PSC. CE is characterized by informal loops of not expired 
medicines, mainly due to health professionals’ initiatives (although this may not be clear 
to participants). This classification emerged from content analysis of 2,622 references 
found in six databases, from which 127 were selected. Three questions guided the review 
in each category: (i) what are the elements of the forward PSC processes that impact PSC 
reverse flows?; (ii) in what stages of the PSC are the reverse flows identified?; (iii) what 
does the academic literature recommend for improving PSC reverse flows? The literature 
shows that excessive amounts and inappropriate types of medicines hinder donations. 
Inventory planning and quality control problems are the main difficulties for medicines 
RL. The circularity of EOU-M is affected significantly by frequent changes of patient 
therapies and health conditions, and by failures of healthcare agents in monitoring 
prescriptions. The proposed classification suggests that the circularity of not expired 
medicines is not yet researched in the field of logistics, supply chain and procurement, 
and it is scarcely considered in engineering, and business and management areas, which 
evokes a call for future research agenda. 
 
Keywords: Pharmaceutical Supply Chain. Medicines wastes. Reverse flows. Reverse 
Logistics (RL). Circular Economy (CE). 
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Introduction 
A Pharmaceutical Supply Chain (PSC) is defined as a “combination of processes, 
organizations and operations involved in the development, design and manufacturing of 
useful pharmaceutical drugs” (Singh et al., 2016: 1). It is one of the most complex supply 
chains, as it relates to the life and the health of individuals (Schiel, 2018), supporting high 
levels of risks, uncertainties and significant asymmetries in information flows throughout 
the chain (Papalexi et al., 2014). PSC brings together thousands of different stakeholders 
with diverse objectives (Halabi and Gostin, 2015), such as, raw material producers, the 
pharmaceutical industry itself, distributors, health agents (hospitals, clinics, physicians, 
insurance health representatives), third party operators, retailers, and customers/patients.  
The pharmaceutical industry is in the mainstream of the healthcare sector (Urias, 2017). 
In global terms, it earns revenues over US$ 825 billion, with average growth of 4% to 6% 





Development Goals due to its complex interfaces with environmental impacts (solid 
waste and wastewater generation from incorrect discharges), human wellbeing (increased 
aging and demographic change that lead to escalating dependency on medicines), and 
social equality aims (contrasting with lack of access, high prices and losses in supply 
chains).  
The literature on SCM reverse flows is very recent (Schenkel et al., 2015), and it is 
associated with terms such as Sustainable Supply Chain Management (SSCM), Green 
Supply Chain Management (GSCM), and Closed Loop Supply Chain (CLSC) (Gurw et 
al., 2015; Xin, 2010). SSCM, proposed as a theory by Pagell and Wu (2009), as a 
framework by Dubey  et al. (2017), and as measurable indicators by Beske-Janssen et al. 
(2015), is the integration of sustainable goals in a supply chain (Nassir et al., 2016; Roy 
et al., 2018). GSCM relates to the the integration of environmental thinking throughout 
the supply chain (Kumar and Kant, 2015; Fang and Zhang, 2018). SSCM is associated 
with governance and social responsibility, and GSCM with a theoretical approach for 
reduction of the negative environmental impacts in a supply chain (Batista et al., 2018; 
Jayaram and Avittathur, 2018). However, both SSCM and GSCM are weakly developed 
as theories (Toublic and Walker, 2015; Dubey et al., 2017). Instead, they are mostly 
realized as practices as Reverse Logistics (RL) or Circular Economy (CE) – the latter also 
being associated with Closed Loop Supply Chains (CLSC) (Govindan and Soleimani, 
2015; 2017; Xin, 2010). 
RL refers to the recovery and racapture of the value of goods once they are deemed useless 
by a consumer, or lose functional characteristics that hinder their appropriate or safe use 
(Agrawal et al., 2015). RL practices involve reuse, repair and remanufacturing (Bouzon 
et al., 2016; Bouzon et al., 2018; Govindan and Bouzon, 2018). Reuse is using a 
functional component from a retired assembly. Repair is bringing damaged components 
back to a functional condition, and remanufacturing is a transformation of used units, 
components or parts to units that satisfy exactly the same quality and other standards as 
new units (Zeqiang and Wenming, 2006). Nonetheless, this sequence depends on the type 
of the targeted product – whether more or less perishable, more or less complex, and so 
on (Beh et al., 2016). RL does not necessarily involve closed loops. In the PSC, for 
instance, RL is usually taken as an activity through which wholesalers or providers collect 
the pharmaceutical wastes and transport them to manufacturers or places for disposal 
(Saravanan and Kumar, 2016; Singh et al., 2016). Although a large number of RL studies 
on PSC have been published, they focus basically on operations of collecting unwanted 
medicines from pharmacies and hospitals (Franco and Alfonso-Lizarazo, 2017).  
CE promotes reduction, reuse and recycling of resources in a supply chain through cleaner 
production principles – whose main premise is the avoidance of wastage. A “circular 
economy is an economy constructed from societal production-consumption system that 
maximizes the service produced from the linear nature-society-nature material and energy 
throughput flow” (Korhonen et al., 2018: 40). Differently from RL, strongly addressed to 
business processes, CE looks to reverse flows in a way that promotes a win-win situation 
in economic, societal and environmental aspects (Genovese et al., 2017). While RL 
associates environmental and financial revenues, it does not necessarily bring social 
benefits (Lai et al., 2013). Therefore, RL is taken as a limited version of CE (Geisendorf 
and Pietrulla, 2018). 
Even considered “superficial and unorganized” (Korhonen et al., 2018: 37), with “vague 
boundaries” (De Jesus et al., 2018: 3021), and devoid of unified theory (Fischer and 
Pascucci, 2017), the concept of CE is framed at a deeper level than the RL idea, resonating 





innovates (Prieto-Sandoval et al., 2017) while re-signifying new forms of uses of goods 
(Reike et al., 2018).  
CE is based on closed loop systems (Urbinati et al., 2017) and on extended value use 
instead of value exchange, therefore it aims at disentangling ecology and economy 
(Bernon et al., 2018). In the PSC, CE could be framed in terms of keeping EOU-M as 
long as possible in the economic and social cycle of use. This is more difficult than EOL-
M RL. In fact, one of the barriers for CE is the complexity of the product management in 
reverse flows of aspects such as quantities, quality, time, pace of returns (Bressanelli et 
al., 2018), and health concerns (Govindan and Hasanagic, 2018). 
Although reverse flows has been receiving increased attention in PSC (Narayana et al., 
2014 a; 2014b; Kumar et al., 2009), it it does not capture the complexity of events and 
relationships related to EOU-M and EOL-M. Basically, aspects involved in planning 
(Serrou et al., 2014), procurement (Sanderson et al., 2015), price formation (Schiel, 
2018), innovation costs (Singh et al., 2016) and other upstream coordination operations 
(Beh et al., 2016; Chen et al., 2018) are detached from losses and wastage in this supply 
chain. It also takes place through collaboration between agents (Daugherty, 2011), in 
vertical and horizontal directions (Soosay and Hyland, 2015), and in inter or 
intraorganizational dimensions (Rebs et al., 2019). Research on medicines returns are 
scattered through the literature under labels as diverse as: medicines/drugs donations 
programs (Nicoli et al., 2018) and its environmental and human implications; Reverse 
Logistics (Campos et al., 2017); Circular Economy (Zhou and Zhang, 2007); and Closed 
Loop Supply Chain (Amaro and Barbosa-Póvoa, 2008). 
The PSC suffers from a lack of unified theoretical approaches, which hinders the 
assessment of its flaws and opportunities for improvement (Halldorson and Kotzab, 
2015). It is a common gap in the field of SCM, which evolved from inventory 
management to production and plannning control, and becoming a specific focus of study 
since the 1990s. PSC is usually studied from its components, as stakeholders, flows, 
relationships, coordination, value, efficiency, and performance (Ahi and Searcy, 2014) 
rather than under a specific theory.  This gap is especially relevant in regards to the reverse 
flows of this chain, and has motivated the look for a classification to better understand 
diferences in reverse activities. 
Considering that the gaps in forward processes in PSC can affect the reverse flows – the 
forms and paths through which used medicines (EOU or EOL) are managed after their 
distribution to patient – this paper undertakes a classificatory review of the literature on 
PSC reverse flows. It aims at addressing the following questions: (i) what are the elements 
of the forward PSC processes that impact PSC reverse flows?; (ii) in what stage of the 
PSC are the reverse flows identified?; (iii) what does the academic literature recommend 
for improving PSC reverse flows? All these questions are framed for the context of EOU-
M and/or EOL-M rather on all products within the PSC. 
The paper is organized as follows. In the next section, the methodological design is 
described and justified; in the third section; results are presented and discussed in two 
parts: descriptive analysis of reviewed documents, and content analysis for each category. 
Conclusions and recommendations for future studies are presented in the fourth section. 
 
   
 





This research adapted methodologies already employed in seminal work (Cormack, 1971) 
and recent work (Littel, 2018) of qualitative-classificatory review combined with review 
procedures offered by the classical academic literature on sustainability in SCM (Seuring 
et al., 2005; Seuring and Müller, 2008).  
Cormack (1971) recommends classificatory review as a means for organizing and solving 
questions. Based on Littel (2018), a classification of reverse flows of EOU-EOL-M is 
proposed taking in to consideration three categories: Donations, RL, and CE. RL and CE 
are presented in academic literature, according the concepts exposed in the Introduction 
section. Donations, on the other hand, can be considered an empirical category because 
they are not consensually conceptualized. 
For the sake of clarity, donations, RL, CE were all associated with SSCM, whose aim is 
to input principles of sustainability (as corporate social responsibility) to SCM. RL and 
CE were both associated with GSCM, as they keep green principles (such as wastage 
avoidance) in the supply chain. CE was additionally associated with CLSC, because it 
seeks the maximum circulation of goods in a supply chain, in order to accomplish both, 
waste avoidance and social benefits. Figure 1 shows the considered scheme for each 
category and their respective links with SCM theories/frames associated with 
sustainability. 
 
<Figure 1 here> 
 
Littel (2018) recommends that classificatory reviews support focus, goals, and coverage. 
The focus of this research are the reverse flows of EOU-EOL-M in three categories, and 
the goals are the answers for the research questions posed in the Introduction. The 
coverage refers to the procedures of collecting the corpus of the literature review: 
databases, established criteria for the types of recovered studies, selected keywords, and 
comprehensiveness in time. A set of six databases was consulted: with Web of Science 
(WoS), Emerald, Wiley, Taylor & Francis, and Science Direct all interrogated across all 
years, and Google Scholar interrogated from 2014. For WoS, we considered only the 
databases of health sciences as PubMed, Medline, SciELO, and CAB Abstracts, which 
includes Global Health and other similar meta databases related to health issues. We did 
not consider other metabases within WoS such as patents directories and others not related 
to health. For Google Scholar, we have limited the search from the last five years 
(including 2019) because of the excessive amount of results and high level of duplicates 
with other databases already included in the scope of this review. The search was carried 
out using the following key expressions: “pharmaceutical supply chain” and 
“drug(s)/medicine(s) donation(s)” (for the first search);  “drug(s)/medicine(s) 
donation(s)” and “reverse logistics” (for the second); and “drug(s)/medicine(s) 
donation(s)” and “circular economy” and “medicines wastage” (for the third). Such key 
expressions were repeated for each database. 
From the overall searches, there were recovered a set of documents, mainly peer reviewed 
articles. A first filter was applied in order to eliminate duplicated articles. Then, for the 
remaining references, the titles and the abstracts were analysed to evaluate whether they 
could provide answers to the three research questions. If so, the respective references 
were selected as the definitive research corpus. 
Final results included mostly peer reviewed papers, along with a small proportion of 
international congress papers and PhD dissertations. The selected references were 





content. Results systematization and analysis followed two strands: a descriptive and a 
content analysis, according to Seuring et al. (2005) and Seuring and Müller (2008). 
For both types of analysis, the seminal works of Seuring et al. (2005) and  Seuring and 
Müller (2008) were partially adopted. According to these authors, the literature review 
for SCM must be explicit, systematic, reproducible, and based on theories. In the current 
research, theories on reverse flows of EOU-EOL-M were not identified in the academic 
literature. That is why a previous classificatory review (shown in Figure 1) was structured, 
following, as best as possible, studies on SSCM, GSCM, and CLSC associated with 
donations, RL and CE of medicines, as indicated in the Introduction. 
For the descriptive analysis, the following information was retrieved: number total of 
selected references published by year; more representative countries in which the research 
is carried out for each considered category; methodologies employed in the studies; and 
number of references by disciplinary field of the selected studies. This last item of the 
descriptive analysis was amplified in Appendices A, B, and C, where the wide range of 
journals involved in the results is listed. The overall results of the descriptive analysis 
was then discussed. 
For the content analysis, the inductive method (categorization after reading the selected 
documents) was employed, which means that the categories emerged from the content. 
Nevertheless, this process was guided by the research questions posed in the introductory 
session of this research. Therefore, the inductive method outlined by Seuring et al. (2005) 
and Seuring and Müller (2008) was adapted. For donations, the results covered: (i) 
constraints (ii), where it occurs in the supply chain; (iii) recommendations for 
improvement. For RL, the content analysis covered: (i) barriers, drivers/opportunities, 
alongside reviews, models, and specific constraints, as emerging subjects; (ii) where it 
occurs in the supply chain; (iii) recommendations for improvement. Finally, for CE, there 
were identified contents as CE and CLSC; CE as epistemical view of social responsibility; 
CE upstream in the chain (green chemical); CE downstream in the chain (packaging and 
bioeconomy), reusing and wastage avoidance; (i) constraints, (ii) where it occurs in the 
supply chain; and (iii) recommendations for improvement. 
The design employed for the methodological procedures is depicted in Figure 2. 
 
<Figure 2 here> 
 
3 Results – Description and Classification 
  
The searches identified 2,622 documents, which were mainly peer reviewed articles. 
After a first filter applied to eliminate duplicated articles and to read the titles and 
abstracts of the remaining articles, 127 references were selected – 12 for the category 
donations; 81 for RL, and and 34 for CE. Table 1 presents details of the quantitative 
results of the review.  
The categorization into donations (DO), RL and CE followed the criteria detailed in 
Figure 1. Donations were considered acts of any person - mainly of corporations and 
humanitarian organizations, carried out for philanthropy or corporate social responsibility 
aimed at providing medicines for needy persons. RL were classified as reverse flows of 
PSC members, mainly distributors, retailers, consumers, in order to accomplish 
regulatory purposes seeking economic gains. CE included recirculation of not expired 
medicines, mainly on the initiative of health professionals and consumers to fulfill needs 







< Table 1 here> 
 
3.1 Descriptive analysis 
 
This analysis, with respect to the framework suggested by Seuring et al. (2005) and 
Seuring and Müller (2008), refers to the following information: total number of selected 
references published by year for each category (Table 2, Figure 3); more representative 
countries in which the research is carried out for each category (Table 3, Figure 4,); 
number of references by the main disciplinary fields of the selected studies (Table 4, 
Figure 5); journals of the publications by category (Appendices A, B, and C); and 
methodologies employed in the studies (Table 5, Figure 6). 
From these data, it is possible to realize that the number of publications on donations has 
low variability, but for RL and CE it shows considerable increase in recent years. For RL, 
a peak was identified in 2014, with stabilization in the following years. For CE, an 
increase from 2017 is apparent. Table 2 and Figure 3 present the details on the chronology 
of the selected publications. 
<Table 2 here> 
<Fig. 3 here> 
 
In the current study, countries were included with at least two references in at least one 
of the considered categories. It is possible to see that research on medicines donations is 
carried out mostly in the US and UK. The situation is similar for RL and CE. The US has 
the highest number of studies on RL, while UK has the highest number on CE (Table 3, 
Figure 4). CE is scarcely researched in the US, which can indicate a contrasting cultural 
reality in the way the American and the British society deal with EOU/EOL-M. 
 
<Table 3 here> 
<Figure 4 here> 
 
From the peer reviewed identified journals in which the research on donations, RL and 
CE was published, those from the pharmacy field are dominant, followed by those from 
the health, the logistics, supply chain and procurement fields. Donations research is 
mostly published in journals of the health field; RL in journals of logistics, supply chain, 
procurement, and engineering areas; CE studies are predominant in journals of pharmacy. 
Table 4 and Figure 5 show the distribution of the publications by knowledge field. The 
lack of CE research published in journals of logistics, supply chain, procurement and 
engineering fields is noticeable, which can indicate that discussion on circularity of 
medicines is out of the scope of those journals. Conversely, CE of medicines is widely 
spread in journals of pharmacy, which raises the possibility that professionals in this field 
are closer to the idea of medicines loops than supply chain managers or engineering 
professionals. In this sense, circularity seems more usual for patients and health 
professionals, regardless of whether they intend to practice the principles of CLSC or to 
simply put in circulation a medicine surplus, avoiding wastage and adjusting the right 
dose and right medicine to the patients’ needs. Appendices A, B, and C show in details 
the journals considered for this research. 
 
<Table 4 here> 






Regarding the methodologies employed, qualitative and survey studies are dominant 
(Table 5, Figure 6). Quantitative methods, case studies and literature review are most 
commonly employed in RL research, whereas surveys are usual for CE. This can indicate 
that RL has more maturity than CE research when related to the subject of EOU/EOL-M. 
 
<Table 5 here> 




3.2 Classificatory analysis 
 
The classificatory analysis is based on a previous systematization of the reviewed 
documents under three categories: Donations, RL, and CE. As argued in the Introductory 
section, reverse flows of goods, including medicines, suffer from the lack of a sound 
theoretical basis for its analysis. In the case of EOU/EOL-M donations, RL, and CE, all 
such categories reflect the ideas of SSCM, which are associated with governance and 
social responsibility. RL and CE, especially, reflect GSCM frameworks, that rely on the 
environmental aspects of the reverse flows. It means that under GSCM principles, the 
returns of medicines, for correct disposal (RL), or for reuse (CE), are both associated with 
wastes avoidance. The circularityof used and not expired medicines corresponds to the 
idea of maximum harnessing of a good through successive loops of reuse, which is 
aligned with CLSC principles. Having such aspects in mind, the classificatory analysis 
was designed to answer three questions for each category: (i) what are the elements of the 
forward PSC processes that impact PSC reverse flows?; (ii) in what stages of the PSC are 
the reverse flows identified?; (iii) what does the academic literature recommend for 
improving PSC reverse flows? The answers, from the literature review, are provided and 
indicated in bold subtopics, in the following subsections for donations (3.2.1), RL (3.2.2), 
and CE (3.2.3). 
 
 
3.2.1 EOU-M Donation Programs 
Medicines donations are old philanthropic practices that probably began with journeys of 
physicians and nurses from developed to developing countries, based on the transport of 
surplus medicines (Smego Jr. and Gebrian, 1994). Such practices can improve the access 
to medicines in middle and low income countries (Attaran, 2004), but there is little impact 
assessment or reported lessons of these initiatives (Jenny et al., 2016). 
Poor coordination hinders the efficacy of many such humanitarian programs (Dolinskaya 
et al., 2018), even at small scales.  Donations are also jeopardized due to lack of capacity 
of health professionals (Chukwu et al., 2016).  
There are several forms of medicines donations, and the motivation and outcomes of such 
types of initiatives are controversial. Humanitarian causes (wars, epidemics) are the 
pivotal reasons behind donations (Collins, 2004; Colatrella, 2008). One of the main 
criticism of medicines donations is the mismatch between what poor communities need 
and what is given (Jenny et al., 2016; Guilbaud, 2018; Nicoli et al., 2018). A typical 





and Herzegovina war (1992-96), during which around 60% of the given medicines were 
misappropriated (Beckmans et al., 1997). It motivated the WHO to issue guidelines for 
best practices in medicines donations, emphasizing the responsibilities of the responsible 
parties (WHO, 2010).  
Beckmans et al. (1997) assessed data on 12 multilateral and non-governmental 
organizations involved in medicines donation, and found four critical situations: useless 
products (irrelevant to the local epidemiological and clinical context), unusable (EOL-M 
at the time of arrival or soon afterward), unidentifiable (not labelled or labelled in 
unknown language), and damaged (in transportation and storage) medicines. Bero et al. 
(2010) analyzed academic literature of medicines donations from 2000 to 2008, and found 
reports of 96 incidents, mainly related to the supply chain transportation and warehousing.  
- Forward flows that affect the reverse 
In the current review, the main identified elements of the forward supply chain that affect 
donations are: excessive production, demand uncertainty and products quality (Attaran, 
2004; Dolinskaya et al., 2018); and package/labelling, transportation and storage failures 
(Beckmans et al., 1997). Appendix D brings more details on this topic. 
- In what stages of the PSC donations occur 
It is difficult to precisely identify in what part of the PSC donations take place. Reviewed 
studies (see Appendix E) indicate that it happens between diverse sources and end users 
(Bero et al., 2010; Nicoli et al., 2018). From the reading of the selected papers, a depiction 
is provided in Figure 7, in order to indicate answers to this question 
  
 
<Fig 7 here> 
 
- Recommendations for improving EOU-M donations 
The review found that collaboration between stakeholders (Kale et al., 2013; Guilbaud, 
2018) and adherence to best practices guidelines (Beckmans et al., 1997) are the core 
suggestions for improving EOU-M donations. Recommendations of each reviewed 
document are expressed in the Appendix F. 
 
 
3.2.2 EOU/EOL-M Reverse Logistics Programs 
EOU/EOL-M can return to the economic cycle through reverse logistics, which “involves 
the collection of goods from end consumers, sorting of goods received, disposal of goods 
and retrieval of components at various stages in the supply chain and remanufacturing 
processes” (Kwateng et al., 2014:17). From the literature review, it is possible to identify 
four main tendencies in EOU/EOL-M studies: barriers related to planning, operational 
aspects, costs, public policies, and culture; drivers and opportunities for improvement; 
models; and review studies. Such barriers are herein presented as answers to the first 
research question of the present study (elements of the forward  PSC that impact reverse 
flows). The loops of the supply chain in which RL occurs are indicated for filling the 
second question. And the identified opportunities and drivers, including models and 
reviews, are described as answers to the third research question (recommendations for 
improvement). 
- Barriers in the forward PSC that affect RL 
Barriers to EOU/EOL-M RL are from several types. Regarding planning and operational 





supply chain, that causes difficulties for coordination between stakeholders;  difficulties 
for management of flows/lack of flexibility; quality control problems (including 
packaging); inventory/production planning problems; excessive production; lack of 
specific medicines availability; procurement problems; storage problems; delivery 
delays; logistics inefficiency; high perishability/low shelf life of medicines. Many 
coordination problems of the PSC that end in reverse flows start as demand and inventory 
failures in forward processes (Singh et al., 2016; Lücker and Seifert, 2017; Abbas and 
Faroquie, 2018; Lima et al., 2018), or in storage and transportation (Bolineni, 2016; He 
et al., 2016), resulting in lack of control over EOU/EOL-M (Mustafa and Potter, 2009; 
Balbino and Balbino, 2011; Kwateng et al., 2014). 
Costs (of operation, distribution, and transportation) and prices (for consumers) are 
deemed relevant barriers of the forward PSC that affects RL (Mwencha et al., 2017). 
Costs can be negatively affected by the presence of third party agents (Rossetti et al., 
2011), diversion of medicines (Nakyanzi et al., 2010; Romero, 2013), counterfeiting (Ali, 
2015; Mackey and Nayyar, 2017), difficulties to monitor the supply chain, given the 
extension and diversity of items (Kongar et al., 2015; Mackey and Nayyar, 2017; 
Narayana et al., 2019), and perishability (Subzwari and Nasir, 2015).  
Public policies barriers of the PSC that jeopardizes RL are: lack of transparency in prices, 
that could be avoided through the adoption of new technologies of traceability (Ding, 
2018); lack of regulatory frames (Khan and Subzwari, 2009; Falqueto and Kligerman, 
2013); defective intellectual protection (Cameron, 2009; Thepsatidsilph, 2015; Urias, 
2015); informal trade/counterfeiting (Li and Hamblin, 2016).  Counterfeiting drugs are 
those that contain “no active ingredient, an incorrect amount of active ingredients, 
incorrect ingredient, and/or unapproved labeling and packaging” (Ziance, 2008: 71). 
Bueno et al. (2017) identify institutional gaps involving producers, distributors, retailers, 
and consumers in PSC that prevent correct procedures for RL taking place. Problems of 
traceability in PSC is an institutional difficulty also described by Enyinda and 
Szmerekovsky (2008) and Enyinda and Tolliver (2009), and by Schiel (2018). Cultural 
constraints are spread all over the PSC, and have pivotal relevance for impeding RL 
processes.  
The identified aspects of cultural barriers are: lack of consumers’ awareness (El-
Hamamsy, 2011; Kifli et al., 2018); lack of innovative culture in downstream parts of the 
PSC for supporting RL (Khan and Subzwari, 2009; Law et al., 2014); lack of 
information/transparency between physicians and patients or prescription problems 
(Trueman et al., 2010; Elliott, 2013); lack of training/capacity building of health 
professionals (Tong et al., 2011); patient behaviour problems, such as non adherence to 
medicines, treatment abandonment, and careless attitudes (Xie and Breen, 2012; Kagashe 
et al., 2014; Vogler et al., 2014; Pereira et al., 2017; Kelly et al., 2018). Appendix G 
shows in details all such barriers and associated studies. 
In summary, inventory/production planning appears as the main constraint of the forward 
PSC that impacts RL (Nematollahi et al., 2017a; 2017b; Narayana et al., 2019, and other 
authors listed in Appendix G, column 4). The second constraint is the extension of the 
supply chain and consequent difficulties of coordination between stakeholders (Masoumi 
and Nagournay, 2012; Li and Hamblin, 2016; Weraikat et al., 2016b, and other authors 
cited in column 1 of Appendix G).  
 
In what stages of the PSC RL occurs 
RL occurs mainly between patients/consumers and pharmacists (Schiel, 2018, and 





H provides the full list of authors that confirm this situation. Some studies indicate 
specifically four points of RL concentration. One lies between industrial internal flows, 
indicating quality assurance problems (Cameron et al., 2009; Serrou et al., 2014; Xie and 
Breen, 2014; Li and Hamblin, 2016; Imran et al., 2018). Another is between pharmacists 
and industry, probably referring to returns of EOL-M or recalls (Nakyanzi et al., 2010; 
Breen and Xie, 2015; Kamba et al., 2017; Nematollahi et al., 2017 a; 2017b, for example). 
A third one is found between pharmacies and third party agents, also for returns or recalls 
(Kongar et al., 2015; Rolewicz-Kalińska, 2016; Singh et al., 2016; Weraikat et al., 2016 
a; 2016b). The fourth is identified between EOU-M donators, from several sources, and 
end users (Trueman et al., 2010; Blackstone et al., 2014; Kagashe et al., 2014; Bekker et 
al., 2018; Kifli et al., 2018) but out of the context of reusing and rather framed as wasted 
medicines. Evidence of direct RL between distributor and industry, and between 
distributor and third parties, was not identified in the literature. Figure 8 provides a 
detailed idea on the stages of the PSC in which RL occurs. 
 
<Fig. 8 here> 
 
 
Opportunities and drivers (recommendations) for RL improvement 
Opportunities for RL improvement start from the forward chain, with coordination among 
stakeholders on the right quantities, distribution places and times (Kraiselburd and Ydav, 
2013; Pinto et al., 2014) and affordable prices (Cameron et al., 2009; Baxerres and 
Hesran, 2011; Schiel, 2018), or with the adoption of cleaner production strategies (Li and 
Hamblin, 2016). Governmental drivers can boost medicines RL. Examples are the 
extended responsibility policy for the PSC implemented in Portugal (Niza et al., 2014), 
the attempts to develop metrics for RL in India (Aghalaya et al., 2012), and the 
recommendation for legislation improvement in China (He et al., 2016). 
Ritchie et al. (2000) reported the benefits of EOU/EOL-M RL in 28 UK hospitals, with 
potential for significant economic savings. Breen and Xie (2015) also reported drivers for 
medicines RL in public hospitals. In Pakistani pharmaceutical industries, Khan and 
Subzwari (2009) found that improvements in the reverse flows could save at least 10% 
of the US$ 5 billion costs of the estimated system.  Medicines procurement improvements 
can be associated with RL processes bringing benefits to the whole supply chain (Foster, 
1991; Nakyanzi et al., 2010; Xie and Breen, 2012, 2014; Sanderson et al., 2015). 
Appendix I brings a list of recommnedations for RL improvements, according to the 
reviewed studies. 
 
Reviews and its contributions 
De Brito et al. (2005) reviewed more than 60 studies on the complex RL relationships, 
including PSC. In another review, Narayana et al. (2014b) concluded that PSC has three 
levels of indirect interaction: among governmental bodies, healthcare purchasing groups, 
and healthcare providers. One of the most comprehensive reviews on medicines RL was 
carried out by Campos et al. (2017). They screened studies from 1996 to 2015, and 
concluded that a systemic set of planning and action, involving all the participants of the 
supply chain, is lacking in the PSC reverse cycle. While earlier studies were focused on 
toxicity, water contamination and risk assessment of incorrect medicines disposal, more 
recent studies address the greening of the supply chain. Lima et al. (2018) reviewed the 
literature on counterfeit drugs and how to tackle this problem. Such reviews, therefore, 






Models for operations improvement 
Many scholars propose RL models for EOU/EOL-M. Amaro and Barbosa-Povoa (2009) 
analyzed different scenarios regarding product demands, price and uncertainties in a 
Mixed Integer Linear Programming. In an early study, these authors have designed 
sequential planning and scheduling of supply chain structures with reverse flows (Amaro 
and Barbosa-Povoa, 2008). Kumar et al. (2009) employed the DEMAIC (Define, 
Measure, Analyse, Improve, Control) approach for analyzing PSC in recalls. Pribluda et 
al. (2014) developed a three level model for avoiding counterfeit medicines. A framework 
for medicines RL linked to RFID was developed by Kongar et al. (2015), although this 
technology has already been recommended since the previous decade in this supply chain 
(Chao et al., 2007; Wyld and Jones, 2007; Tzeng et al., 2008). A model for EOL 
medicines disposal, after a literature review, is designed by Kumar and Saravanan (2016). 
Ding (2018) proposes the introduction of 4.0 manufacturing in PSC for improving 
sustainability. 
Rolewicz-Kalińska (2016) proposed a framework for efficient medical operation of 
medical wastes. Moslemi et al. (2017) developed a comprehensive, multi-objective 
mathematical model in the healthcare supply chain considering quality and green 
concepts. Weraitak et al. (2016a) suggested a valuation system for second-hand 
medicines (EOU/EOL), stratified acording to the term of expiry. In another study, 
Weraikat et al. (2016b) indicated avenues for assessment of costs for collecting, reusing, 
recycling, and final disposal of EOU/EOL-M. Nematollahi et al. (2017a) argue that in 
improving the balance of stocks in forward logistics, it is possible to avoid wastes through 
simultaneous coordination of the medicines retailer’s service level and the respective 
supplier’s visit interval in a two-echelon PSC. Collaborative support between supplier 
and retailer is pivotal for achieving a better performance in the PSC (Nematollahi et al., 
2017b). Nevertheless, distributors and retailers have different interests, so the balance of 
flows can be hindered (Narayana et al., 2014b; Nematollahi et al., 2018). Finally, Imran 
et al. (2018) proposed a medicine supply chain model for an integrated healthcare system 
considering time, quality and costs, and the perspective of consumers, which is when RL 
starts. These diverse models indicate that scholars are trying to optimize structures and 
means for RL in PSC, although they get limited by the issues of extension of the supply 
chain and volatility in collaboration. 
 
3.2.3. Circular Economy (CE) and CLSC involving EOU-M 
 
CE is not explicitly referenced in the PSC literature, although the idea of circularity or 
CLSC is presented as reuse (Alhamad et al., 2018; Connelly, 2018), return of medicines 
(Daniszewsi et al., 2002; AlSamanhodi et al., 2017) and even in the market of medical 
devices (Bange and Morgan, 2018). Søndergaard et al. (2006) argue that the practice of 
medicines returns for reuse can reduce overall health costs and time at hospital, although 
with no positive impacts for medicines market prices.  
Medicines CE appears indirectly in reference to the organic chemical industry, having 
pharmaceuticals as a branch (Zhang, 2017), and to green chemicals (Andrews et al., 2010; 
Jimenez-Gonzalez et al., 2011; Koenig et al., 2018), in the upstream of the PSC. Trends 
in CE retrieved from the literature review can be classified as those generally and those 
strictly linked to the PSC. Usually, CE approaches advocate a new epistemical view of 
social responsibility. Strictly, CE is identified in both upstream and downstream of the 





in the latter. A third strict approach is EOU-M wastage reduction or avoidance. These 
findings were organized as follows, in order to answer the research questions with respect 
to CE.  
 
 
Barriers to the forward PSC that affect EOU-M CE 
CE is a type of epistemic view of sustainability, which integrates cleaner production and 
social responsibility principles. In fact, welfare disconnected from the traditional linear 
economy (production-consumption) represents a new perspective for industrial sectors 
and its supply chains (Hens et al., 2018). Alexandru and Tasnadi (2014) state CE as a 
blue economy, where the consumption of the resources go beyond the usual 
product/services pushing. A non-waste society (Hesmati, 2015), one of the principles of 
the CE, implies loops that keep goods circulating as much as possible through integrative 
strategies (Wang et al., 2018). It includes substitutable products (Hosseini-Motlagh et al. 
(2018) and product/wastes symbiosis (Ezura et al., 2016).  
CE is also represented as Logistics Social Responsibility (Mani et al., 2018) while 
embracing practices of corporate social responsibility (Yin and Jamali, 2016) or 
responsible management of the supply chain (Miao et al., 2012). It is indeed named 
socially responsible CLSC (Modak et al., 2018). All these nominations indicate forms of 
ethical practice inclusion in supply chains that surpass the idea of a reverse flow for 
business, as usually intended for RL.  
Engaging consumers to provide easier access to medicines, for instance, is in line with 
CE principles (Tang, 2018). In the context of EOU-M, reusing becomes increasingly 
relevant, as significant quantities of medicines which are not yet expired are left over in 
homes, pharmacies, warehouses, clinics, hospitals, and other parts of the PSC. Such a 
perspective can be seen as paradoxical through a conventional business lens (van 
Bommel, 2018). These ethical and economic aspects are, arguably, relevant barriers for 
medicines circularity. Given the increasing need of new products lauchning and fierce 
market competition in PSC, CE seems an invisible, sometimes forgotten and even 
repressed process in the context of EOU-M. In the current research, the main barriers 
identified for medicines reuse are linked to the variability of the products’ quality (Rees, 
2011; Lorenzini et al., 2017, among others); to the lack of medical prescriptions 
monitoring (West et al., 2014; Hampson and Ottey, 2015; McRae et al., 2016), and to 
impasses linked to prescriptions duration versus changes in patients conditions (Taitel et 
al., 2012; King et al., 2018). These aspects are represented in detail in Appendix J. What 
is noticeable, with respect to contraints for CE of medicines, is that the literature focuses 
on the end of the supply chain. It exposes the constraints faced by pharmacists and other 
health professionals that try to harness the value of used, not expired, medicines while 
managing regulatory and other formal aspects of the public health sector.  
 
In what stages of the PSC CE occurs 
The circularity of EOU-M is higher between patients, physicians or other health 
professionals (Petty et al., 2014 and others). Between patients and pharmacists it is also 
very common (West et al., 2015, for example), and during or after patients’ consumption 
(AlSamanhodi et al., 2017 and others). Appendix K presents details about the common 
loops of the supply chain where EOU-M circulate for reusing. Circularity seems to be 
higher in informal relationships, which does not mean it is disorganized (Twigg et al., 





figure, it is possible to identify the main points of the loops’ concentration in the PSC for 
the CE of medicines. 
 
<Fig 9 here> 
 
Opportunities and drivers (recommendations) for CE improvement  
There are several opportunities for reusing EOU-M. It is a reality through specific 
legislation, as adopted for return programs in 37 States of the US (Connelly, 2018), or 
through small initiatives in hospitals (Toh and Chew, 2016), since ethical and technical 
protocols are followed for avoiding risks (Alhamad et al., 2018). Nevertheless, a broad 
research on qualitative aspects of medicines reuse and wastage is scarce (Bekker et al., 
2017; West et al., 2014). Such opportunities can be easily hindered by situations such as 
treatment discontinuation and dispensing of medicines in higher than necessary quantities 
(AlSamanhodi et al., 2017; Gyanendra et al., 2011).  
According to Daniszewsi et al. (2002), campaigns on unwanted medicines disposal have 
existed since the 1970s, but they remain a problem. These authors analyzed eight 
communities regarding medicines use and concluded that longer than 30 days 
prescriptions and therapies change are the key causes of wastage. This is a similar finding 
to King et al. (2018), observing that there is no ideal frequency for issuing prescriptions, 
as already indicated by Taitel et al. (2012). Petty et al. (2014), on the other hand, 
concluded that 28 days was the maximum limit for prescriptions to prevent wastage. 
However, this is at odds with those who find treatment adherence seems to be better with 
longer prescriptions (White et al., 2010; King et al., 2018), which creates a conflict with 
environmental care. O’Leary et al. (2006) warns that few health experts care about the 
lifestyles of beneficiaries, advising them on the risks of interactions in the simultaneous 
use of several drugs.  
Self-management strategies, changes in medical conditions and over-collection due to 
fear of future necessity, are causes of medicines wastage related to patient behaviour 
(Jesson et al., 2005; Singh et al., 2011).  
Reducing wastage of medicines and improving healthcare are not necessarily opposed, 
but are difficult to align (Taylor 2010, 2014), especially considering the dynamics of 
patients response for each treatment. New technologies that identify the right medicine 
dosage at the right time, are alternatives for wastage of medicines (Bange and Morgan, 
2018), although are not widely accessible. The opportunities for EOU-M circularity, 
therefore, lies mainly on the way patients and health professionals manage and value 
medicines that can be reused under careful supervision. It is recommended that 
pharmacists get as close as possible to patients in order to monitor presciptions and usage 
of medicines (Latif et al., 2013; Shah et al., 2014; West et al., 2014).  
The drivers for EOU-M circularity are basically from upstream and downstream in the 
PSC. In the first case, initiatives for recycling raw materials upstream in the PSC started 
in the middle of the past decade by the American Chemical Society (ACS) (Andrews et 
al., 2010), and more than US$ 2 million have been invested in this field since then (Koenig 
et al., 2018). Practices, such as intensity mass control in processes (Jimenez-Gonzalez et 
al., 2011), are examples of the engagement of PSC in the CE principles. Cleaner 
production in PSC is aligned with green chemistry (Ze-hua et al., 2011).  
In the second case, two situations were identified in the current review: packaging design 
and bioeconomy. Packaging design is crucial for avoiding wastage of EOU/EOL-M. 
Stringent regulation is a major force for innovation in such respects, followed by 





market, design, and the environment. Social and ethical aspects of packaging, although 
becoming relevant with the aging of the population and with the rise of new needs for 
medical treatments, are still overlooked. Technological change in packaging occurs after, 
or at the same time as, the product innovation, because the costs for focussing only on 
packaging change are high. Schaefer and Cheung (2018) advocate the development and 
use of smart packages for extending the shelf-life, monitoring the freshness, and 
displaying detailed information about products. 
Regarding bioeconomy of surplus medicines, it could be adopted as the source for some 
raw materials, such as phosphate (Carraresi et al., 2018) or perishable products, such as 
food (Frigo and Lucchini, 2018), always respecting the quality control parameters (Kane 
et al., 2018). The last alternative under cleaner production principles would be EOU/EOL-
M destruction using techniques such as pyrolysis (De Filippis et al., 2012) for energy 
harnessing.  
Recommendations for boosting EOU-M circularity are detailed in Appendix L, where it 
is clear that the main aspect is the management and monitoring of prescriptions by 
pharmacists or other health professionals (White et al., 2010; Shah et al., 2010, and 
others). Providing investments in capacity building and cleaner production initiatives in 
the PSC are also advised (De Filippis et al., 2012 and others). 
 
 
 4 Discussion, conclusions, and recommendations for future research 
 
The comprehensive literature review, descriptive and classificatory analysis of the PSC 
reverse flows presented in this study casts light on the complexities of the processes and 
relationships that pose difficulties for a robust sustainable management of medicines that 
are considered wastes in this supply chain. Firstly, EOU and/or EOL-M are not common 
terms associated with reverse flows in the PSC. The assumption behind this research is 
that, due to the extended nature of the supply chain, the diversity and large number of 
stakeholders, and the scattered configuration of the flows in forward processes, the PSC 
is subject to several barriers affecting the development of reverse flows of medicines. It 
consequently hinders the adoption and the support of sustainable supply or green supply 
chain management initiatives throughout the chain, from the raw material procurement 
and upstream production processes through to the final use of medicines. 
From the descriptive analysis, it was possible to unveil the predominance of authorship 
from the UK and the US in medicines reverse flows. Furthermore, it was found that 
journals of the pharmacy field are dominant, and that journals of logistics, supply chain, 
procurement, and engineering rarely give space to publications of medicines CE issues.  
Although the academic studies on PSC in its reverse flows are increasing, they do not 
portray such flows as effective, and the bulk of specific literature relates to the restricted 
number of echelons in this supply chain. Research on medicines reverse flows is more 
robust when related to mathematical models for inventory control and collaboration 
between stakeholders, in the early or middle stages of the supply chain, rather than in the 
late stages when consumers, physicians, pharmaceutical companies and other healthcare 
agents play decisive but often uncoordinated roles in the destination of EOU/EOL-M. In 
the final steps of the downstream supply chain, successful examples tend to be small-
scale and context-specific cases. 
Also, the difficulty in finding studies on EOU/EOL-M in a given type of journal was 
evident: such studies are spread through diverse thematic sources of publication. It can 





theoretical basis. In fact, the whole reverse supply chain management field is a recent 
academic and empirical construct that portrays pieces of frameworks from SSCM, GSCM 
and CLSC.  
This research made clear the need for a previous categorization of the reviewed studies 
in donations, RL and CE while assuming that the diferences among such reverse flows 
constructs, although outlined, still needs more clarity. The assumption behind the current 
categorization is that SSCM serves as an umbrella for all types of medicines reverse 
flows, while GSCM fits more to RL and CE (as both pursue environmental aims), and 
CE is the only reverse flow that can support CLSC principles – such as, for instance, the 
attempt to maximize the harnessing of used and not expired medicines.   
In the context of EOU/EOL-M, RL usually refers to collection of pharmaceutical items, 
mainly expired, for correct disposal, while donations and CE look for win-win situations 
between agents of the PSC. In this respect, donations and mainly CE are moved by 
ecological and ethical reasons, with the sense of maximizing use value, and are both 
decoupled from economic value pursued in RL. Nevertheless, donations are still strongly 
linked to philanthropic and social corporate responsibility of companies, or to 
humanitarian action for emergency situations, while CE is practiced predominantly 
through informal relationships of the PSC stakeholders. In contrast to donations, which 
do not necessarily entail orientations for medicines reuse, CE involves mainly health 
professionals, that supervise and try to find strategies for medicines reuse, and patients 
with difficulties in affording medicines and patients that lack specific knowledge on how 
to best manage their medical prescriptions, avoiding losses. Nonetheless, even circularity 
does not prevent wastage at all: it is more an ideal than a reality. Research on the number 
of times an EOU-M keeps circulating from owner to owner in the end of the PSC were 
not found under the scope of this review. 
The current research posed questions on the elements of the forward chain that impact 
reverse flows; on the stages of the supply chain in which the reverse flows take place; and 
on the recommendations for improving reverse flows. In such respects, it was found that 
EOU-M returns are constrained mainly due to poor coordination, even at small scales, in 
the supply channels that are presumably designed to manage donations. Mismatches 
between what is donated and what is really needed by patients are the main problem. 
Useless, unidentified, damaged products hinder the quality of donations. Improving 
collaboration and adherence to specific guidelines are the recommendations for 
increasing donations. 
Inventory/production planning problems, and the large extent of the PSC appear as the 
main difficulties for EOU/EOL-M RL, which occur mostly between patients/consumers 
and physicians or other health professionals, and after the final consumption. In contrast 
to donations and RL, CE is not clearly referenced in the literature in relation to EOU-M, 
but it is instead associated with CLSC or circularity – this latter expression being more 
common. The principal expressions of CE in the PSC are green chemistry, in upstream 
parts of the supply chain, and in new trends in packaging and bioeconomy, in downstream 
parts. It is possible to foresee tendencies in respect of circularity looking to studies of 
food supply chain CE that has in common with medicines the aspect of perishability. In 
this respect, CE maintains some similarities with donations, because the aim of the reverse 
flow is to help end users while reducing environmental impacts. CE of medicines takes 
place mostly between patients, physicians or other health professionals, and this type of 
circularity is designed as informal loops, not at all closed, because for this it would be 





This study presents some limitations. The first one regards the difficulties in undertaking 
a comprehensive and, at the same time, representative academic literature review. It was 
necessary to combine diverse expressions in order to find significant studies in the broad 
scope of reverse flows in PSC. Terms, such as, “end-of-use” and “end-of-life”, even when 
combined with “medicines” or “drugs”, were not efficient for the designed purpose of the 
research. The second constraint is the fact that dealing with a very large and complex 
supply chain, results in very diverse fields of research being included in the search 
findings. This enriched the classification, but at the same time, made it a difficult task.  
Special attention must be given to the first question that motivated this research. The fact 
that coordination and collaboration have appeared as the main barriers to the forward flow 
of the PSC that affects the reverse flows (whether donations, RL, or CE) indicates that it 
is very reasonable to suppose that problems of forward PSC are also the roots of reverse 
flow barriers in this supply chain. 
For future research, it is recommended to deepen this line of investigation that tries to 
link factors and aspects of the forward PSC that resonate in the reverse channels. It is 
necessary, for instance, to design studies that can support particular hypotheses on this 
causal relationships in order to bring more robust evidence to test such assumptions. 
From our results, we also recommend that editors of journals which embrace the topics 
of logistics, supply chain, procurement, and operations management (engineering), pay 
attention to the topic of CE as a form of reverse flow as being an important element of 
RL. Finally, we recommend more studies that can shed light on how the circularity of 
medicines can be made more visible and spread through all stages of the reverse PSC. 
Particularly, we recommend the investigation of how health professionals (mainly related 
to pharmaceuticals) have or have not been prepared to deal with the practices of the CE 
since their academic formation, and how they can improve their contribution to reduce 
medicines wastage in reverse flows. It is particularly necessary to increase the amount  
and the quality of studies on capacity building and knowledge management of such 
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Figure 1 - Categories of medicines reverse flows and associated SCM concepts 
SSCM – Sustainable Supply Chain Management; GSCM – Green Supply Chain Management;  CLSC – Closed Loop Supply Chain; 
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Sources: Adapted from Cormack (1971),  
Littel (2018), 







FOCUS – Reverse flows of EOU-EOL-M in PSC through classificatory 
review. 
Categories of reverse flows: Donations (DO), Reverse Logistics (RL), 
and Circular Economy (CE). 
GOALS  - Answer the questions for each category: 
(i) What are the elements of the forward PSC processes that impact PSC 
reverse flows? (Constraints) 
(ii) In what stage of the PSC are the reverse flows identified?  
(iii) What does the academic literature recommend for improving PSC 
reverse flows?  
COVERAGE – Web of Science, Emerald, Wiley, Taylor & Francis, 





Number total of selected references published by year. 
More representative countries in which the research is carried out for 
each category. 
Number of references by disciplinary field of the selected studies. 
Methodologies employed in the studies. 
Journals of the publications by category (Appendices). 
 
CLASSIFICATORY ANALYSIS – ANSWERS 
 
DONATIONS – (i) Constraints (ii), where occurs (iii), 
recommendations for improvement. 
RL – (i) Barriers, drivers/opportunities, [reviews, models, specific 
constraints*], (ii) where occurs, (iii) recommendations for improvement. 
CE – [CE and CLSC, CE as epistemical view of social responsibility, 
CE upstream the chain (green chemical), CE downstream the chain 
(packaging and bioeconomy), reusing and wastage avoidance], (i) 
constraints, (ii) where occurs, (iii) recommendations for improvement. 
 

























































Figure 4 – Main countries in which medicines reverse flows research is carried out 
 
DO = donations; RL = Reverse Logistics; CE = Circular Economy 
There were considered countries with at least 2 occurrencies in at least one of the categories 
 
 
Figure 5 – Number of references by disciplinary fields of the selected publications 
 
 
























            Figure 6 – Methodologies employed in the reviewed documents 
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[1], [2], [3], [7], [11], 
[14] 









[1] Between several sources of donators 
(industry, intermmediaries) and needy people;  
[2] Between industry and needy people 
(involving intermediaries); 
 [3]  Between distributors and hospitals’ 
pharmacies;  
[4] Between healthcare unities/professionals 
and  and needy persons; 
 [5] Between humanitarian organizations and 
needy people. 
Number between brackets in the above figure 
are associated to the authors listed in the 
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[1]Between industrial internal flows; [2] Between 
industry and raw material producers (suppliers);  
[3] Between third party agent and industry; [4] Between 
distributor and industry; [5] Between pharmacists and 
industry; [6] Between hospital pharmacies and patients; 
[7] Between hospital pharmacies and industry;  
[8] Between pharmacies and third party agents;  
[9] Between patients/consumers and pharmacists;  
[10] Between pharmacists and distributors;  
[11] Between patients and health clinics; [12] Between 
consumers and distributors; [13] Between physicians 
and other health professionals; [14] Between patients 
and physicians; [15] Between EOU-M donators (from 
several sources) and needy patients, with or without 
intermediaries; [16] All over the supply chain; [17] After 
final consumption (not informed receiver); [18] 
Information not available. 
Number between brackets in the above figure are 
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[30], [31], [37], [45], 
[48], [49], [50], [53], 
[56], [57], [61], [62], 
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[1]Upstreaming the chain, in medicines production;  
[2]Between pharmaceutical industry and package supplier;  
[3] Between patients and pharmacists;  
[4] Between pharmacists, patients and needy people;  
[5] Between patients, physicians or other health professionals (nurses);  
[6] Between several sources of EOU-M donations and a health clinic;  
[7] During or after the patients’ consumption;  
[8] All over the supply chain. 
Number between brackets in the above figure are associated to the authors 











Key expressions Web of 
Science(1) 








Any time Any time Any time Any time Any time Since 2014  
























27 14 63 0 32 7 0 0 72 3 477 10 34 
Total  241 38 126 13 169 10 83 2 644 26 1,359 38 127 
(1)The search in Web of Science (WoS) was limited to CAB Abstracts/Global Health, Medline and PubMed. Other meta-bases of WoS, as Inspec  
(for engineering and technological issues), Food Science Technology Abstracts, Patent and Data Collections, Regional Hosted Collection, Specialty  
Collections (Current Contents, BIOSIS Citation, BIOSIS Preview, Biological Abstracts and Zoological Records), were not included.  








Table 2 – N of publications by year for each category 
Year  DO RL CE 
1991 1 1 0 
1994 1 0 0 
2000 0 1 0 
2002 0 0 1 
2004 2 0 0 
2005 0 1 1 
2006 0 0 2 
2007 0 2 0 
2008 1 4 0 
2009 0 6 0 
2010 1 2 3 
2011 0 5 4 
2012 0 3 2 
2013 1 4 1 
2014 0 13 4 
2015 0 9 3 
2016 2 9 2 
2017 0 11 5 
2018 3 9 6 
2019 0 1 0 
            
             DO – Donations; RL – Reverse Logistics; CE – Circular Economy 
 
 
Table 3 - Main countries in which the research on medicines reverse flows is carried out 
 
Country DO RL CE Total 
US 6 17 4 27 
UK 2 13 21 36 
Australia 0 3 0 3 
Brazil 0 7 0 7 
Canada 0 3 0 3 
China 0 1 2 3 
France 1 2 0 3 
Iran 0 4 0 4 
Pakistan 0 3 0 3 
Portugal 0 4 0 4 
The Netherlands 0 4 2 6 
 
                       DO = donations; RL = Reverse Logistics; CE = Circular Economy 
                          There were considered countries with at least 2 occurrencies in at least  


































DO – Donations; RL – Reverse Logistics; CE – Circular Economy 
 
Table 5 – Methodologies employed in the reviewed documents 
 
Methodology DO RL CE Total 
Qualitative 4 30 12 46 
Quantitative 0 11 2 13 
Survey 4 6 14 34 
Review 1 15 3 20 
Case Study 1 10 3 14 
 









Field DO RL CE Total 
Pharmacy 1 11 13 25 
Health 6 5 5 16 
Logistics, Supply Chain and Procurement 1 15 0 16 
Engineering 0 14 1 15 
Environmental 0 9 2 11 
Medicine 1 4 5 10 
Innovation and Development 1 2 3 6 
Business and Management 0 5 1 6 





            Appendix A – Donations - Authorship by country 
                                 and source of publication 
 
Authorship Country Source/Journal 
Attaran (2004) UK Health Affairs 
Beckmans et al. 
(1997) 
Belgium The New England Journal 
of Medicine 
 Bero et al. (2010) US Bulletin of the WHO 
Chukwu et al. 
(2016) 
Nigeria Research in Social and 
Administrative Pharmacy 
Colatrella (2008) US Annals of the Tropical 
Med. & Parasitology 
Collins (2004) US Perspectives in Biology 
and Medicine 
Dolinskaya et al. 
(2018) 
US, Germany Jounal of Humanitarian 
Logistics and Supply 
Chain Management 
Guilbaud (2018) France Journal of International 
Political Theory 
Jenny et al. (2016) US Globalization and Health 
Kale et al. (2013) UK Innovation and 
Development 
Nicoli et al. (2018) Italy Int. Health 
Smego and 
Gebrian(1994) 








Appendix B – Reverse Logistics - Authorship by country and source of publication 
REVERSE LOGISTICS 
Authorship Country Journal/Source 
Abbas and Faroquie (2018) Oman, India International Journal of Logistics 
Economics and Globalisation 
Abidi et al. (2015) The Netherlands, UK, 
Germany 
Journal of Humanitarian Logistics and 
Supply Chain Management 
Aghalaya et al. (2012) India, New Zealand Australian and New Zealand Academy of 
Management Conference. Proceedings 
Ali (2015) Norway Doct. Dissertation 
Amaro and Barbosa-Povoa (2008) Portugal Computers and Chemical Engineering 
Amaro and Barbosa-Povoa (2009) Portugal Computers and Chemical Engineering 
Balbino and Balbino (2011) Brazil Âmbito Jurídico [Legal Field] 
Baxerres and Hesran (2011) France Social Science and Medicine 
Bekker et al. (2018) The Netherlands Int. J. Clin. Pharm 
Blackstone et al. (2014) US Am. Health Drug Benefits 
Bolineni (2016) US Doct. Dissertation 
Bueno et al. (2017) Brazil South American Development Society 
Journal 
Bravo and Carvalho (2015) Portugal Int.J. Procurement Management 
Breen and Xie (2015) UK Int. J.Procurement Management 
Cameron et al. (2009) Switzerland The Lancet 
Campos et al. (2017) Brazil Supply Chain Management: An 
International Journal 
Chao et al. (2007) Taiwan Technovation 
De Brito et al. (2005) The Netherlands Book chapter (Springer) 
Ding (2018) UK Process Safety and Environmental 
Protection 
El-Hamamsy et al. (2011) Egypt International Journal of Pharmaceutical 
Studies and Research 
Elliot (2013) UK The Journal of Global Business Issues 
Enyinda and Szmerekovsky (2008) Arabian Emirates, US Prescriber. The Journal of Prescribing 
and Medicines Management 
Enyinda and Tolliver (2009) Arabian Emirates , US Journal of African Business 
Falqueto and Kligerman (2013) Brazil Ciência & Saúde Coletiva [Science & 
Collective Health] 
Foster (1991) UK Soc. Sci. Med. 
Franco and Alfonso-Lizarazo 
(2017) 
Colombia, France Hindawi Complexity 
Halabi and Gostin (2015) US Book chapter, Academic Press 
He et al.(2016) China Procedia Environmental Sciences 
Imran et al. (2018) South Korea, Pakistan Journal of Manufacturing Systems 
Kagashe et al. (2014) Tanzania . Journal of Applied Pharmaceutical 
Science 
Kamba et al. (2017) Uganda Bulletin World Health Organ 
Kelly et al. (2018) Australia, New Zealand BMC Public Health 
Khan and Subzwari (2009) Pakistan South Asian Journal of Management 
Sciences 
Kifli et al. (2018) Brunei Asian Journal of Pharmaceutical and 
Clinical Research 
Kongar et al. (2015) US, Turkey Information Technology & Management 
Kraiselburd and Ydav (2013) Costa Rica, US Production and Operations Management 
Kumar et al. (2009) US Int. Journal of Productivity and 
Performance Management 
Kumar and Saravanan (2016) India World Journal of Pharmacy and 
Pharmaceutical Sciences 
Kwateng et al. (2014) Ghana Global Journal of Business Research 
Law et al. (2014) US Research in Social and Administrative 
Pharmacy 
Lima et al. (2018) Brazil Supply Chain Management: An 
International Journal 
Li and Hamblin (2016) UK Journal of Cleaner Production 
 Lücker and Seifert (2017) Switzerland Omega 
Mackey et al. (2017) US Expert Opinion on Drug and Safety 
Masoumi and Nagournay (2012) US Transportation Research E 







Mustafa and Potter (2009) UK Supply Chain Management: An 
International Journal 
Nakyanzi et al. (2010) Uganda Bulletin of The World Health 
Organization 
Narayana et al. (2014 a) India The International Journal of Logistics 
Management 
Narayana et al. (2014 b) India Journal of Purchasing & Supply 
Management 
Narayana et al. (2019) India Journal of Cleaner Production 
Nematollahi et al. (2017a) Iran Journal of Cleaner Production 
Nematollahi et al. (2017b) Iran Int. J.Production Economics 
Nematollahi et al. (2018) Iran, UK, Malaysia, 
Singapore 
Journal of Cleaner Production 
Niza et al. (2014) Portugal Journal of Cleaner Production 
Papalexi et al. (2014) UK Annual Conference Special Issue for the 
Logistics Research Network (LRN), 
Wyley 
Pereira et al. (2017) Brazil Environ.Sci.Pollut. Res. 
Pinto et al.  et al. (2014) Brazil Eng. Sanit. Ambient. 
Pribluda et al. (2014) US Pharmaceutical Regulatory Affairs 
Ritchie et al. (2000) UK Supply Chain Management: An 
International Journal 
Rolevick-Kalińska (2016) Poland Transportation Research Procedia 
Romero (2013) Canada Proceedings of the World Congress on 
Engineering and Computer Science, Vol 
II 
 Rossetti et al. (2011) US International Journal of Physical 
Distribution & Logistics Management 
Sanderson et al. (2015) UK Health Services and Delivery Research 
Saravanan and Kumar (2016) India Indian Journal of Research in Pharmacy 
and Biotechnology 
Serrou et al. (2014) Morroco Journal of Scientific & Engineering 
Research 
Schiel (2018) US BrighamYoung University Law Review 
Singh et al. (2016) India International Journal of Pharmaceutical 
and Healthcare Marketing 
Subzwari and Nasir (2015) Pakistan South Asian Journal of Management 
Sciences 
Thepsatidsilph (2015) Australia Doct. Thesis 
Tong et al. (2011) New Zealand Environment International 
Trueman et al. (2010) UK Report,  YHEC/School of Pharmacy, 
University of London 
Tzeng et al. (2008) Taiwan Int. J. Production Economics 
Urias (2017) The Netherlands Book chapter, Emerald Insight 
Vogler et al. (2014) Austria Journal of Pharmaceutical Policy and 
Practice 
Weraikat et al. (2016 a) Canada Int. J. Productions Economics 
Weraikat et al. (2016 b) Canada Computers & Industrial Engineering 
Wyld and Jones (2007) US . Int. J. Integrated Supply Management 
Xie and Breen (2012) UK Supply Chain Management: An 
International Journal 
Xie and Breen (2014) UK Supply Chain Management: An 
International Journal 






           Appendix C – Circular Economy - Authorship by country and source of publication 
  Authorship Country Journal/Source 
Alhamad et al. (2018) UK International Journal of 
Pharmacy Practice 
AlSamanhodi et al. 
(2017) 
Saudi Arabia Tropical Journal of 
Pharmaceutical Research 
Andrews et al. (2010) UK, US, Ireland, 
Belgium 
Organic Process Research 
& Development 
Bange and Morgan (2018) UK Geriatric Medicine Care 
Bekker et al. (2017) The Netherlands Int. J. Clin. Pharm. 
Connelly (2018) UK The Pharmaceutical 
Journal. A Royal 
Pharmaceutical Society 
Publication 
Daniszewsi et al. (2002) UK International Journal of 
Pharmacy Practice 
De Filippis et al. (2012) UK WIT Transactions on 
Ecology and the 
Environment 
Gyanendra et al. (2011) India International Research 
Journal of Pharmacy 
Hampson and Ottey 
(2015) 
UK Prescriber 
Jesson et al. (2005) UK Primary Health Care 
Research and 
Development 
Jimenez-Gonzalez et al. 
(2011) 
US Organic Process Research 
& Development 
Kane et al. (2018) The Netherlands Resources Conservation 
and Recycling 
King et al. (2018) UK, Germany British Journal of General 
Practice 
Koenig et al. (2018) US, UK Organic Process Research 
& Development 
Latif et al. (2013) UK Administrative Pharmacy 
Lorenzini et al. (2017) Sweden Journal of Business 
Research 
McRae et al. (2016) UK Int.J.Pharm. Practice 
Mwencha et al. (2017) Tanzania, US Global Health: Science 
and Practice 
O’Leary et al. (2006) UK Int.J.Pharm. Practice 
Petty et al. (2014) UK BMC Health Services 
Research 
Shah et al. (2014) UK Journal of Community 
Nursing 
Søndergaard (2006) Denmark Value in Health 
Taitel et al. (2012) US Medicare and Medicaid 
Research Review 
Taylor (2010) UK The Pharmaceutical 
Journal 
Taylor (2014) UK Prescriber 
Toh and Chew (2016) Singapore Palliative Medicine 
Twigg et al. (2015) UK International Journal of 
Pharmacy Practice 
West et al. (2014) UK Int. J. Clin. Pharm 
West et al. (2015) UK, Malta Eur. J. Hosp. Pharm 
White et al. (2010) UK International Journal of 
Pharmacy Practice 
Ze-hua et al. (2011) China Energy Procedia 
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Appendix E – Where EOU-M Donations takes place in PSC 
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al. (2017) 
             X           
[29] Chao et al. 
(2007) 
                X    X    
[30] De Brito et 
al. (2005) 
X                        
[31] Ding 
(2018) 
X          X   X  X       X  
[32] El-
Hamamsy et al. 
(2011) 
                        
[33] Elliot 
(2013) 

















    X            X        
[37] Foster 
(1991) 
      X        X          
[38] Franco and 
Alfonso-
Lizarazo (2017) 
           X             
[39] Halabi and 
Gostin (2015) 
X                        
[40] He et al. 
(2016) 
    X                    
[41] Imran et al. 
(2018) 
  X                      
[42] Kagashe et 
al. (2014) 
                       X 
[43] Kamba et 
al. (2017) 
   X                     
[44] Kelly et al. 
(2018) 
                       X 
[45] Khan and 
Subzwari 
(2009) 
          X   X   X X       
[46] Kifli et al. 
(2018) 
   X                     
[47] Kongar et 
al. (2015) 




X           X             
[49] Kumar et 
al. (2009) 
        X                
[50] Kumar and 
Saravanan 
(2016) 
                    X    
[51] Kwateng et 
al. (2014) 
X       X    X             
[52] Law et al. 
(2014) 
                   X     
[53] Lima et al. 
(2018) 
X X            X           
[54] Li and 
Hamblin (2016) 
  X                X      
[55] Lücker and 
Seifert (2017) 








X        X   X             
[58] Moslemi et 
al. (2017) 




   X                     
[60] Nakyanzi 
et al. (2010) 
              X      X    
[61] Narayana 
et al. (2014 a) 
    X                    
[62] Narayana 
et al. (2014 b) 
 X X                      
[63] Narayana 
et al. (2019) 











Planning/operational constraints: (1) Extension of the supply chain/difficulties for coordination between stakeholders; (2) Difficulties for flows 








   X                     
[67] Niza et al. 
(2014) 
             X  X         
[68] Papalexi et 
al. (2014) 
    X                    
[69] Pereira et 
al. (2017) 
                       X 
[70]  Pinto et al.  
et al. (2014) 
    X                    
[71] Pribluda et 
al. (2014) 
  X                      
[72] Ritchie et 
al. (2000) 
      X                  
[73] Rolevick-
Kalińska (2016) 
                        
[74] Romero 
(2013) 
        X    X            
[75] Rossetti et 
al. (2011) 
         X    X           
[76] Sanderson 
et al. (2015) 
  X    X                  
[77]Saravanan 
and Kumar 
    X                    
[78] Schiel 
(2018) 
         X        X X      
[79] Serrou et 
al. (2014) 
       X                 
[80] Singh et al. 
(2016) 








                 X       
[83] Tong et al. 
(2011) 
                      X  
[84] Trueman et 
al. (2010) 
                     X  X 
[85] Tzeng et al. 
(2008) 
   X                     
[86] Urias 
(2017) 
     X            X       
[87] Vogler et 
al. (2014) 
                       X 
[88] Weraikat et 
al. (2016 a) 
   X                 X    
[89] Weraikat et 
al. (2016 b) 
X             X           
[90] Wyld and 
Jones (2007) 
  X                    X  
[91] Xie and 
Breen (2012) 
                      X X 
[92] Xie and 
Breen (2014) 
                        
[93] Ziance 
(2008) 





production; (6) Lack of specific medicines availability; (7) Procurement problems; (8) Storage problems; (9) Delivery delays; (10) Logistics 
inefficiency;  
(11) High perishability/low shelf life of medicines. Costs/prices constraints: (12) High costs of operation;  
(13) High costs of distribution; (14)  High costs of transportation;  (15) High prices for consumers.  
Public policies constraints: (16) Lack of transparency in prices; (17) Lack of regulatory frames;  
(18) Defective intellectual protection; (19) Informal trade/counterfeiting. Cultural constraints:  
(20) Lack of consumers’ awareness; (21) Lack of innovation culture;  
(22) Lack of information/transparency between physicians and patients or presciption problems;  
(23) Lack of training/capacity building of health professionals; (24) Patient behaviour problems  
(non adherence to medicines, treatment abandonment, careless attitudes).  







                                    Appendix H - Where EOU/EOL-M RL takes place in PSC 
Stage of the 






























         X         
[14] Abidi et 
al. (2015) 
               X   
[15]Aghalaya 
et al. (2012) 
               X   
[16] Ali 
(2015) 
















           X       
[21] Bekker et 
al. (2018) 




              X    
[23] Bolineni 
(2016) 
                 X 
[24] Bueno et 
al. (2017) 








    X              
[27] Cameron 
et al. (2009) 
X                  
[28] Campos 
et al. (2017) 
                X  
[29] Chao et 
al. (2007) 
      X    X        
[30] De Brito 
et al. (2005) 
                X   
[31] Ding 
(2018) 




        X          
[33] Elliot 
(2013) 


















                X  
[37] Foster 
(1991) 








X                  
[40] He et al. 
(2016) 
                X  
[41] Imran et 
al. (2018) 
X                  
[42] Kagashe 
et al. (2014) 
              X    
[43] Kamba et 
al. (2017) 
    X              
[44] Kelly et 
al. (2018) 
                X  
[45] Khan and 
Subzwari 
(2009) 
               X   
[46] Kifli et 
al. (2018) 
              X    
[47] Kongar 
et al. (2015) 





               X   
[49] Kumar et 
al. (2009) 





               X   
[51] Kwateng 
et al. (2014) 
        X          
[52] Law et 
al. (2014) 
                X  
[53] Lima et 
al. (2018) 
               X   
[54] Li and 
Hamblin 
(2016) 













               X   
[58] Moslemi 
et al. (2017) 




         X         
[60] Nakyanzi 
et al. (2010) 
    X              
[61] Narayana 
et al. (2014 a) 






et al. (2014 b) 
               X   
[63] Narayana 
et al. (2019) 
               X   
[64] 
Nematollahi 
et al. (2017a) 
    X              
[65] 
Nematollahi 
et al. (2017b) 
    X              
[66] 
Nematollahi 
et al. (2018) 
         X         
[67] Niza et 
al. (2014) 
               X   
[68] Papalexi 
et al. (2014) 
        X          
[69] Pereira et 
al. (2017) 
               X   
[70]  Pinto et 
al. et al. 
(2014) 
                X  
[71] Pribluda 
et al. (2014) 
               X   
[72] Ritchie et 
al. (2000) 





        
X 
          
[74] Romero 
(2013) 
     X             
[75] Rossetti 
et al. (2011) 









        X          
[78] Schiel 
(2018) 
        X          
[79] Serrou et 
al. (2014) 
X                  
[80] Singh et 
al. (2016) 








        X          
[83] Tong et 
al. (2011) 
        X          
[84] Trueman 
et al. (2010) 
        X     X X    
[85] Tzeng et 
al. (2008) 
               X   
[86] Urias 
(2017) 
               X   
[87] Vogler et 
al. (2014) 
                X  
[88] Weraikat 
et al. (2016 a) 
       X           
[89] Weraikat 
et al. (2016 b) 








               X   
[91] Xie and 
Breen (2012) 
X                  
[92] Xie and 
Breen (2014) 
               X   
[93] Ziance 
(2008) 
               X   
[1]Between industrial internal flows; [2] Between industry and raw material producers (suppliers); [3] Between third party agent and industry; 
[4] Between distributor and industry;[5] Between pharmacists and industry; [6] Between hospital pharmacies and patients; [7] Between hospital 
pharmacies and industry; [8] Between pharmacies and third party agents; [9] Between patients/consumers and pharmacists; [10] Between 
pharmacists and distributors; [11] Between patients and health clinics; [12] Between consumers and distributors;[13] Between physicians and 
other health professionals; [14] Between patients and physicians; [15] Between EOU-M donators (from several sources) 
and needy patients, with or without intermediaries; [16] All over the supply chain; [17] After final consumption (not informed receiver); [18] 



















1 2 3 4 5 6 7 8 9 10 11 12 13 
[13] Abbas and 
Faroquie (2018) 
            X 
[14] Abidi et al. 
(2015) 
 X            
[15]Aghalaya et 
al. (2012) 
  X           
[16] Ali (2015)       X       
[17] Amaro and 
Barbosa-Povoa 
(2008) 
  X           
[18] Amaro and 
Barbosa-Povoa 
(2009) 









X        X  X   
[21] Bekker et 
al. (2018) 
     X       X 
[22] Blackstone 
et al. (2014) 
   X          
[23] Bolineni 
(2016) 
    X         
[24] Bueno et 
al. (2017) 
 X X           
[25] Bravo and 
Carvalho (2015) 
X             
[26] Breen and 
Xie (2015) 
     X        
[27] Cameron et 
al. (2009) 
             
[28] Campos et 
al. (2017) 
            X 
[29] Chao et al. 
(2007) 
 X            
[30] De Brito et 
al. (2005) 
   X          
[31] Ding 
(2018) 
         X    
[32] El-
Hamamsy et al. 
(2011) 
           X  
[33] Elliot  
(2013) 




















      X       
[38] Franco and 
Alfonso-
Lizarazo (2017) 
  X           
[39] Halabi and 
Gostin (2015) 
    X  X       
[40] He et al. 
(2016) 
  X           
[41] Imran et al. 
(2018) 
 X            
[42] Kagashe et 
al. (2014) 
    X     X    
[43] Kamba et 
al. (2017) 
      X X      
[44] Kelly et al. 
(2018) 
      X       
[45] Khan and 
Subzwari 
(2009) 
         X   X 
[46] Kifli et al. 
(2018) 
   X          
[47] Kongar et 
al. (2015) 




        X     
[49] Kumar et 
al. (2009) 
            X 
[50] Kumar and 
Saravanan 
(2016) 
  X           
[51] Kwateng et 
al. (2014) 
         X   X 
[52] Law et al. 
(2014) 
 X  X X         
[53] Lima et al. 
(2018) 
     X        
[54] Li and 
Hamblin (2016) 
X X            
[55] Lücker and 
Seifert (2017) 








 X  X          
[58] Moslemi et 
al. (2017) 




          X   
[60] Nakyanzi 
et al. (2010) 
            X 
[61] Narayana 
et al. (2014 a) 
X            X 
[62] Narayana 
et al. (2014 b) 
        X    X 
[63] Narayana 
et al. (2019) 
















      X       
[67] Niza et al. 
(2014) 
X    X         
[68] Papalexi et 
al. (2014) 
     X        
[69] Pereira et 
al. (2017) 
     X        
[70]  Pinto et al. 
et al. (2014) 
X             
[71] Pribluda et 
al. (2014) 
         X    
[72] Ritchie et 
al. (2000) 
     X X       
[73] Rolevick-
Kalińska (2016) 
X             
[74] Romero 
(2013) 
 X            
[75] Rossetti et 
al. (2011) 
          X   
[76] Sanderson 
et al. (2015) 




        X     
[78] Schiel 
(2018) 
X             
[79] Serrou et 
al. (2014) 
    X         
[80] Singh et al. 
(2016) 








     X X       
[83] Tong et al. 
(2011) 
           X  
[84] Trueman et 
al. (2010) 
   X          
[85] Tzeng et al. 
(2008) 
 X            
[86] Urias 
(2017) 
           X  
[87] Vogler et 
al. (2014) 
 X X           
[88] Weraikat et 
al. (2016 a) 
 X X           
[89] Weraikat et 
al. (2016 b) 
  X           
[90] Wyld and 
Jones (2007) 
     X        
[91] Xie and 
Breen (2012) 
 X            
[92] Xie and 
Breen (2014) 
       X      
[93] Ziance 
(2008) 
      X       
 
(1) Improving quality control and management inventory in supply chain; 
 (2) Improving collaboration and coordination in PSC;  
(3) Implementing mathematical models for collaboration improvement, costs minimization,  
uncertainty reduction; (4) Adopting top technologies production and traceability  
(4.0 manufacturing and RFID); (5) Reducing transportation and storage;  





(7) Improving action against counterfeiting; (8) Extending medicines shelf life;  
(9) Educating health professionals and consumers for prevention of incorrect  
EOU/EOL-M discharge; (10) Improving procurement processes; (11) Improving quality  
of prescriptions and communication between physicians and patients;  
(12) Improving RL systems; (13) Creating protocols for correct medicines discharges.  







               Appendix J - Barriers of the forward PSC chain that impact EOU-M CE  
Identified 








    
Sources 
1 2 3 4 5 6 7 8 9 10 11 12 
[94] Alhamad et 
al. (2018) 
X            
[95] AlSamanhodi 
et al. (2017) 
 X       X    
[96] Andrews et 
al. (2010) 
      X      
[97] Bange and 
Morgan (2018) 
 X   X X       
[98] Bekker et al. 
(2017) 
        X X   
[99] Connelly 
(2018) 
  X          
[100]  Daniszewsi 
et al. (2002) 
         X   
[101] De Filippis 
et al. (2012) 
   X         
[102] Gyanendra 
et al. (2011) 
  X          
[103] Hampson 
and Ottey (2015) 
        X  X X 
[104] Jesson et al. 
(2005) 
        X    
[105] Jimenez-
Gonzalez et al. 
(2011) 
     X X      
[106] Kane et al. 
(2018) 
   X    X     
[107] King et al. 
(2018) 
         X X X 
[108] Koenig et 
al. (2018) 
    X        
[109] Latif et al. 
(2013) 
        X  X X 
[110] Lorenzini et 
al. (2017) 
X X  X         
[111]McRae et al. 
(2016) 
           X 
[112] Mwencha et 
al. (2017) 
  X          
[113] O’Leary et 
al. (2006) 
  X          
[114] Petty et al. 
(2014) 
         X X X 
[ 115] Rees 
(2011) 
X  X  X  X      
[116] Shah et al. 
(2014) 
        X   X 
[117] 
Søndergaard et al. 
(2006) 
 X X          
[118] Taitel et al. 
(2012) 
         X X  
[119] Taylor 
(2010) 







       X  X X X 
[121] Toh and 
Chew (2016) 
  X     X     
[122] Twigg et al. 
(2015) 
         X  X 
[123] West et al. 
(2014) 
     X       
[124] West et al. 
(2015) 
        X    
[125] White et al. 
(2010) 
        X X   
[126] Ze-hua et 
al. (2011) 
     X       
[127] Zhang 
(2017) 
    X        
(1) Quality assurance of the product; (2) Constraints of forecasting/variability  
of product; (3) High prices of medicines; (4) Technological barriers;  
(5) Need of high amount of R&D investments;  
(6)Environmental impacts of production/use of products;  
(7) Need for green chemistry initiatives;  
(8) Safety concerns/risks for patients; (9) Patients behaviours  
(over-collection, self-management); (10) Therapy/treatment change; changes  
in medical conditions; (11) Prescription duration versus change in patients 
conditions; (12) Lack/failures in monitoring of prescription by pharmacist 







                       Appendix K - Where EOU-M CE takes place in PSC 
Stage of the 
PSC in which 





    
Sources 
[1] [2] [3] [4] [5] [6] [7] [8] 
[94] Alhamad et 
al. (2018) 




      X  
[96] Andrews et 
al. (2010) 
      X  
[97] Bange and 
Morgan (2018) 
      X  
[98] Bekker et 
al.(2017) 
  X X X    
[99] Connelly 
(2018) 




  X      
[101] De Filipis 
et al. (2012) 
      X  
[102] 
Gyanendra et al. 
(2011) 




    X    
[104] Jesson et 
al. (2005) 
  X      
[105] Jimenez-
Gonzalez et al. 
(2011) 
X        
[106] Kane et 
al. (2018) 
      X  
[107] King et al. 
(2018) 
    X    
[108] Koenig et 
al. (2018) 
X        
[109] Latif et al. 
(2013) 
  X      
[110] Lorenzini 
et al. (2017) 
 X       
[111] McRae et 
al. (2016) 
     X   
[112] Mwencha 
et al. (2017) 
   X     
[113] O’Leary 
et al. (2006) 
     X   
[114] Petty et 
al. (2014) 
    X    
[115] Rees 
(2011) 
       X 
[116] Shah et al. 
(2014) 




     X   
[118] Taitel et 
al. (2012) 







    X    
[120] Taylor 
(2014) 
    X    
[121] Toh and 
Chew (2016) 
     X   
[122] Twigg et 
al. (2015) 
      X  
[123] West et 
al. (2014) 
  X  X    
[124] West et 
al. (2015) 
  X  X    
[125] White et 
al. (2010) 
  X  X    
[126] Ze-hua et 
al. (2011) 
       X 
[127] Zhang 
(2017) 
X        
[1]Upstreaming the chain, in medicines production;  
[2]Between pharmaceutical industry and package supplier;  
[3] Between patients and pharmacists;  
[4] Between pharmacists, patients and needy people;  
[5] Between patients, physicians or other health professionals (nurses);  
[6] Between several sources of EOU-M donations and a health clinic;  
[7] During or after the patients’ consumption;  







          Appendix L - Recommendations for EOU-M CE 










    
Sources 
1 2 3 4 5 6 7 8 
[94] Alhamad et 
al. (2018) 




   X     
[96] Andrews et 
al. (2010) 
X        
[97] Bange and 
Morgan (2018) 
      X  
[98] Bekker et 
al. (2017) 
        
[99] Connelly 
(2018) 




   X     
[101] De 
Filippis et al. 
(2012) 
X        
[102] 
Gyanendra et al. 
(2011) 




   X     
[104] Jesson et 
al. (2005) 
   X     
[105] Jimenez-
Gonzalez et al. 
(2011) 
X        
[106] Kane et 
al. (2018) 
X        
[107] King et al. 
(2018) 
   X     
[108] Koenig et 
al. (2018) 
X        
[109] Latif et al. 
(2013) 
    X    
[110] Lorenzini 
et al. (2017) 
       X 
[111] McRae et 
al. (2016) 
 X X     X 
[112] Mwencha 
et al. (2017) 
 X       
[113] O’Leary 
et al. (2006) 
        
[114] Petty et al. 
(2014) 







X X X      
[116] Shah et al. 
(2014) 




        
[118] Taitel et 
al. (2012) 
   X     
[119] Taylor 
(2010) 
   X     
[120] Taylor 
(2014) 
    X    
[121] Toh and 
Chew (2016) 
     X   
[122] Twigg et 
al. (2015) 
   X     
[123] West et al. 
(2014) 
 X       
[124] West et al. 
(2015) 
 X    X   
[125] White et 
al. (2010) 
 X  X     
[126] Ze-hua et 
al. (2011) 
X        
[127] Zhang 
(2017) 
X        
(1) Improving investments and capacity building in cleaner  
production, green chemistry and related technologies;  
(2) Improving capacity building of health professionals;  
(3) Improving communication between patient and health  
professionals; (4)Improving management and monitoring  
of prescription by pharmacists or other health professionals  
(quantities, duration etc); (5) Creating campaigns for  
patients’ education in EOU-M handling;  
(6) Creating protocols for EOU-M management;  
(7) Customizing medicines to patients;  
(8) Improving packaging. 
 
 
 
 
 
